AMEX · Biotechnology

Armata Pharmaceuticals, Inc. (ARMP) Stock

$4.64 -0.43% AMEX: ARMP Healthcare

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology enterprise with a global focus on creating specialized bacteriophage therapeutics.

Valuation

MetricValue
Price$4.64
Market Cap$170.34M
P/E Ratio-0.60
P/B Ratio-0.55
P/S Ratio57.83
EPS (TTM)$0.00
52-Week High$16.34
52-Week Low$2.35
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE162.59%
ROA-404.89%
ROCE-61.46%
Gross Margin-620.00%
Operating Margin-620.00%
Net Margin-95.54%
Debt/Equity-1.20
Current Ratio1.22

Annual Financials (USD)

Metric20212022202320242025
Revenue$4.0M$6.0M$5.0M$5.0M$5.0M
Operating Profit$-24.0M$-37.0M$-41.0M$-42.0M$-31.0M
Net Profit$-23.0M$-37.0M$-69.0M$-19.0M$-174.0M
EPS$-0.96$-1.08$-1.91$-0.52$-4.80
Op Margin-532.5%-670.8%-902.9%-820.2%-636.7%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$70.0M$108.0M$98.0M$86.0M$77.0M
Total Liabilities$44.0M$72.0M$130.0M$134.0M$295.0M
Cash$10.0M$15.0M$14.0M$9.0M$9.0M
Borrowings$38.0M$49.0M$120.0M$127.0M$288.0M

Latest News

Armata Pharma Reaches FDA Agreement on Pediatric Study Plan for AP-SA02 MT Newswires · Jul 13, 2026 Armata Pharmaceuticals Receives Agreement from FDA on Initial Pediatric Study Plan for AP-SA02 for the Treatment of Complicated Staphylococcus aureus Bacteremia PR Newswire · Jul 13, 2026 Sector Update: Healthcare Stocks Mixed Pre-Bell Tuesday MT Newswires · Jun 23, 2026 Armata Pharmaceuticals Receives Additional $2.5 Million in Funding From US Department of Defense MT Newswires · Jun 23, 2026 Armata Pharmaceuticals Receives $2.5 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support AP-SA02 PR Newswire · Jun 23, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-24.0M$-32.0M$-47.0M$-38.0M$-26.0M
Investing Cash Flow$-3.0M$-4.0M$-16.0M$-4.0M$-1.0M
Financing Cash Flow$-1.0M$0$0$0$0
Net Cash Flow$1.0M$5.0M$-2.0M$-4.0M$-1.0M
Free Cash Flow$-25.0M$-35.0M$-56.0M$-39.0M$-26.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.01
EV / EBITDA-2.13
FCF Yield-15.26%
Quick Ratio1.22
Interest Coverage-1.82
Return 1Y71.18%
Return 3Y216.13%
Return 5Y3.16%

Ownership

Insiders Held68.55%
Institutions Held10.46%
Institutions Float Held33.25%
Institutional HolderSharesReport Date
Madison Asset Management, LLC2,107,6752026-03-31
Vanguard Capital Management LLC366,0282026-03-31
Millennium Management Llc257,9922026-03-31
683 Capital Management LLC137,0002026-03-31
Geode Capital Management, LLC114,5552026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
CCCC $3.52 -0.85% -2.54 $389.20M 0.00%
CDXS $1.47 -2.00% -5.06 $133.62M 0.00%
GNFTGenfit S.A. $8.95 +4.07% 261.07 $445.68M 0.00%
IMDXInsight Molecular Diagnostics Inc. $4.70 -0.84% -3.13 $151.76M 0.00%
IPHAInnate Pharma S.A. $1.79 +0.14% -2.89 $168.32M 0.00%

About Armata Pharmaceuticals, Inc.

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology enterprise with a global focus on creating specialized bacteriophage therapeutics. Its primary objective is to tackle infections that have developed resistance to standard antibiotics. The company's innovative treatments are developed utilizing its exclusive bacteriophage-based technology platform. Within its product pipeline are several significant candidates: AP-SA02, designed for the treatment of Staphylococcus aureus bacteremia; AP-PA02, targeting Pseudomonas aeruginosa; and AP-PA03, intended to address pneumonia. Additionally, Armata has forged a collaborative agreement with Merck & Co. to further the development of synthetic bacteriophage candidates aimed at specific, yet unrevealed, infectious disease agents. The company's main offices are located in Marina del Rey, California.

Armata Pharmaceuticals, Inc. is led by CEO Deborah L. Birx, employs 60 people, headquartered in US, publicly traded since 1994.

Armata Pharmaceuticals, Inc. (ARMP) stock trades at $4.64 with a market capitalization of $170.34M. The stock is valued at a price-to-earnings (P/E) ratio of -0.60, price-to-book of -0.55, price-to-sales of 57.83. Over the past 52 weeks the stock has ranged between $2.35 and $16.34, and currently trades 71.6% below its 52-week high.

On profitability, Armata Pharmaceuticals, Inc. generates a return on equity (ROE) of 162.59% — well above the market average, a sign of a high-quality business, return on capital employed of -61.46%, an operating margin of -620.00%, a net profit margin of -95.54%.

Official website: www.armatapharma.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides